Protagonist Therapeutics (MEX:PTGX) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:PTGX Protagonist Therapeutics Inc MEX:PTGX
47 GF Score
Price MXN1,565.33
GF Value MXN776.69
! 8 Warning Signs
View Full Analysis

What is Protagonist Therapeutics FFO per Share?

FFO per Share only applies to REITs.

MEX:PTGX
47GF Score
Protagonist Therapeutics Inc MEX:PTGX
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Protagonist Therapeutics (MEX:PTGX) Overvalued in 2026?

Based on GuruFocus' analysis, Protagonist Therapeutics stock appears to be overvalued. The current stock price of MXN1,565.33 is trading 101.5% above its estimated GF Value™ of MXN776.69.

Key valuation signals for MEX:PTGX:

  • FFO per Share:
  • GF Value™: MXN776.69 vs. price of MXN1,565.33 (101.5% above fair value)
  • GF Score™: 47/100 with 8 warning signs

No single metric tells the full story. See the MEX:PTGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Protagonist Therapeutics Business Description

Other Exchanges PTGX:USA
Address 7707 Gateway Boulevard, Suite 140, Newark, CA, USA, 94560
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
47GF Score

Get the complete analysis for MEX:PTGX

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,565.33
Price
MXN776.69
GF Value